Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Unit of Urology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Clin Genitourin Cancer. 2021 Jun;19(3):237-245.e2. doi: 10.1016/j.clgc.2020.08.007. Epub 2020 Aug 13.
Patients with advanced seminoma have an exceedingly favorable prognosis. Studies aiming to reduce the total treatment burden and side effects in patients with well-defined disease and very good prognosis are warranted.
In a prospective observational study, patients with advanced stage seminoma were treated with bleomycin, etoposide, and cisplatin (BEP) or EP according to guidelines. Fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET/CT) examinations were performed at baseline, after 2 cycles (PET/CT2) in all patients, and after chemotherapy at the physician's discretion. Disease response to treatment assessed by PET/CT was qualitatively evaluated by 2 independent nuclear medicine physicians. Contrast-enhanced CT scans were also performed according to guidelines (at baseline, after treatment, during follow-up). The study's primary endpoint was to evaluate the association between PET/CT2 findings and relapse-free survival.
From January 2009 to January 2017, a total of 75 consecutive patients were enrolled, of whom 70 were included for analysis. The clinical disease stage was IIA-B and IIC-III in 40% and 60%, respectively. By local assessment, 46 PET/CT2 scans (65.7%) were reported as negative, and 46% of these patients had stage IIC-III disease. Five-year relapse-free survival of PET/CT2-positive patients was 75% (95% confidence interval, 60-95) compared to 97.8% (95% confidence interval, 93.7-100) of PET/CT2-negative patients (P = .002). In univariate analyses, PET/CT2 was significantly associated with relapse-free survival (P = .02).
No residual FDG uptake after 2 cycles of conventional chemotherapy is prognostic in advanced seminoma, but it may be useful to optimize the standard prognostic risk groups and may be tested within larger prospective clinical trials of chemotherapy deescalation.
晚期精原细胞瘤患者的预后极好。对于具有明确疾病和极好预后的患者,有必要进行旨在降低总治疗负担和副作用的研究。
在一项前瞻性观察性研究中,根据指南,晚期精原细胞瘤患者接受博来霉素、依托泊苷和顺铂(BEP)或 EP 治疗。所有患者均在基线时、第 2 周期后(PET/CT2)以及根据医生的判断在化疗后进行氟脱氧葡萄糖正电子发射断层扫描和计算机断层扫描(FDG-PET/CT)检查。两名独立的核医学医师通过 PET/CT 评估治疗反应来定性评估疾病反应。根据指南还进行了增强 CT 扫描(基线时、治疗后、随访期间)。该研究的主要终点是评估 PET/CT2 结果与无复发生存率之间的关联。
从 2009 年 1 月至 2017 年 1 月,共纳入 75 例连续患者,其中 70 例纳入分析。临床疾病分期分别为 40%的 IIA-B 和 60%的 IIC-III。根据局部评估,46 例(65.7%)PET/CT2 扫描报告为阴性,其中 46%的患者为 IIC-III 期疾病。PET/CT2 阳性患者的 5 年无复发生存率为 75%(95%置信区间,60-95),而 PET/CT2 阴性患者为 97.8%(95%置信区间,93.7-100)(P=.002)。单因素分析显示,PET/CT2 与无复发生存率显著相关(P=.02)。
在常规化疗 2 个周期后无残留 FDG 摄取对晚期精原细胞瘤具有预后意义,但它可能有助于优化标准预后风险组,并且可能在更大的化疗降阶临床试验中进行测试。